JPMorgan Chase & Co. downgraded ResMed Inc. (NYSE:RMD) to Neutral in a report released today.
- Updated: September 19, 2016
JPMorgan Chase & Co. has downgraded ResMed Inc.(NYSE:RMD) to Neutral in a report released on 9/19/2016.
Yesterday ResMed Inc. (NYSE:RMD) traded 0.87% lower at $63.77. RMD’s 50-day average is $68.27 and its 200-day average is $61.72. With the last close up 3.53% from the 200-day moving average, compared with the S&P 500 which has decreased -0.01% over the same time. 1,243,258 shares of the stock exchanged hands, up from ann average trading volume of 936,747.
Recent Performance Graphic:
With a total market value of $0.0, ResMed Inc. has a 52 week low of $49.11 and a one-year high of $70.90 with a price-earnings ratio of 26.
In addition to JPMorgan Chase & Co. reporting it’s price target, a total of 11 analysts have issued a ratings update on the company. The one year target is $59.06 with one analyst rating the company a strong buy, four analysts rating the stock a buy, eight analyts rating the stock a hold, two analysts rating the company to underperform, and lastly 0 brokeragesrating the stock as sell.
More About ResMed Inc. (NYSE:RMD)
ResMed Inc. is a holding company. The Company, through its subsidiaries, designs, manufactures and markets equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. The Company develops a range of products for sleep-disordered breathing and other respiratory disorders, including airdevices, informatics solutions, diagnostic products, mask systems, headgear and other accessories. The Company owns interest in Inova Labs Inc., a medical device company specializing in the development and commercialization of oxygen therapy products. The Company holds interest in Brightree LLC, a provider of business management and clinical software applications for the post-acute care industry. The Company’s manufacturing operations are located in Australia, Singapore, France, Germany, and Malaysia and the United States.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.